← All Sponsors
SPONSOR

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Total Trials
1
Recruiting
1
Phases
Phase 3
Conditions studied: HER2-positive Breast Cancer
NCT06313086 Phase 3
Recruiting

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

HER2-positive Breast Cancer
China View Trial →